- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
BNT327/PM8002 Plus Chemo Is Active in Unresectable Pleural and Peritoneal Mesothelioma
June 4th 2025, 4:24pm
Frontline BNT327/PM8002 plus chemotherapy was effective and safe in patients with unresectable pleural and peritoneal mesothelioma.
Fruquintinib Plus Chemotherapy and PD-1 Inhibition Is Safe and Active in Treatment-Naive HER2– Gastric/GEJ Adenocarcinoma
June 4th 2025, 12:00pm
Fruquintinib plus chemotherapy and a PD-1 inhibitor was safe and effective in patients with untreated HER2-negative advanced gastric/GEJ cancer.
NXC-201 CAR T-Cell Therapy Displays Early Activity in Relapsed/Refractory Light Chain Amyloidosis
June 3rd 2025, 10:58pm
The first CAR T-cell therapy designed for patients with relapsed/refractory AL amyloidosis showed feasibility and early efficacy and safety signals.
Dostarlimab Plus Cobolimab Improves MPR Rate vs Dostarlimab in High-Risk Resectable Melanoma
June 3rd 2025, 10:55pm
Dostarlimab plus cobolimab bested dostarlimab monotherapy in terms of MPR and RFS in patients with high-risk resectable melanoma.
Adjuvant Encorafenib/Binimetinib Is Well Tolerated and May Reduce Recurrence Risk in BRAF V600–Mutant Melanoma
June 3rd 2025, 10:50pm
Adjuvant encorafenib/binimetinib was well tolerated with a manageable toxicity profile in patients with high-risk, stage IIB/C BRAF V600-mutant melanoma.
Dr Rathkopf on the Efficacy of Niraparib Plus Abiraterone Acetate/Prednisone in HRR-Altered mCSPC
June 3rd 2025, 10:00pm
Dana E. Rathkopf, MD, discusses the efficacy of niraparib plus abiraterone acetate and prednisone in patients with mCSPC and HRR gene alterations.
Elranatamab Plus Daratumumab and Lenalidomide Is Active in Transplant-Ineligible Multiple Myeloma
June 3rd 2025, 10:00pm
Elranatamab plus daratumumab and lenalidomide was safe and effective in transplant-ineligible patients with newly diagnosed multiple myeloma.
Exploratory Analysis From CALLA Study Highlights Potential Utility of ctDNA in Locally Advanced Cervical Cancer
June 3rd 2025, 9:46pm
An exploratory analysis showed a reduction in the risk of progression in locally advanced cervical cancer with undetectable ctDNA levels after treatment.
One-Third of Patients With R/R Myeloma Are Progression Free at ≥5 Years With Cilta-Cel
June 3rd 2025, 9:40pm
A single infusion of cilta-cel led to a 5-year PFS in patients with heavily pretreated relapsed/refractory myeloma in long-term follow-up of CARTITUDE-1.
Dara-KRd Boosts MRD Negativity Rates in Newly Diagnosed Multiple Myeloma
June 3rd 2025, 9:30pm
Dara-KRd improved rates of MRD negativity compared with KRd alone in patients with newly diagnosed multiple myeloma, regardless of transplant eligibility.
Olaparib Plus Radium-223 Generates Superior rPFS in CRPC
June 3rd 2025, 9:01pm
Olaparib/radium-223 demonstrated superior rPFS outcomes compared with radium-223 alone in patients with castration-resistant prostate cancer.
Perioperative IMNN-001 Plus Chemo Yields Improved Survival Trends in Newly Diagnosed Advanced Epithelial Ovarian Cancer
June 3rd 2025, 8:28pm
Perioperative IMNN-001 plus chemotherapy generated numerical survival improvements in newly diagnosed epithelial ovarian cancer.
CAN-2409 Plus EBRT Bests EBRT Alone in High-Risk Localized Prostate Cancer
June 3rd 2025, 8:10pm
CAN-2409 plus prodrug and radiation therapy significantly improved DFS vs radiation therapy alone in intermediate-to-high-risk prostate cancer.
Adjuvant Nivolumab Plus Relatlimab Misses the Mark in Resected Stage III to IV Melanoma
June 3rd 2025, 7:33pm
Relatlimab plus nivolumab did not improve RFS over nivolumab alone in resected stage III to IV melanoma, per the final phase 3 RELATIVITY-098 results.
Darolutamide Plus ADT Confers HRQOL Benefits in Metastatic Hormone-Sensitive Prostate Cancer
June 3rd 2025, 6:10pm
A PRO analysis showed that darolutamide plus ADT improved HRQOL outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.
SC Daratumumab Plus VRd Displays Durable Efficacy in Newly Diagnosed, Transplant-Eligible Myeloma
June 3rd 2025, 5:42pm
Daratumumab plus VRd continued to demonstrate improvements in MRD negativity and PFS in newly diagnosed, transplant-ineligible multiple myeloma.
Ziftomenib Yields Complete Responses Regardless of Prior Therapy in NMP1-Mutant AML
June 3rd 2025, 5:05pm
Ziftomenib monotherapy elicited clinically meaningful, MRD-negative responses, including CRs, in heavily pretreated, relapsed/refractory NPM1-mutant AML.
Consolidation Benmelstobart ± Anlotinib Provides Substantial PFS Benefits in Stage III NSCLC
June 3rd 2025, 2:28pm
Benmelstobart with or without anlotinib boosted progression-free survival after chemoradiotherapy in unresectable stage III non–small cell lung cancer.
Neoadjuvant Nivolumab Plus Chemo Significantly Improves OS Vs Chemo in Resectable NSCLC
June 3rd 2025, 2:25pm
Neoadjuvant nivolumab plus chemo significantly improved OS vs chemo alone in resectable NSCLC, supporting practice-changing potential.
Niraparib/Abiraterone Is Effective for HRR+ Metastatic Castration-Sensitive Prostate Cancer
June 3rd 2025, 12:00pm
Niraparib plus abiraterone acetate and prednisone improved rPFS vs abiraterone acetate and prednisone and placebo in patients with mCSPC with alterations in HRR genes.